标题
Precision medicine in breast cancer: reality or utopia?
作者
关键词
Breast cancer, Molecular subtypes, Triple-negative, HER2+, Tumor heterogeneity, Precision medicine, Chemotherapy, Immunotherapy, Phase III clinical trials
出版物
Journal of Translational Medicine
Volume 15, Issue 1, Pages -
出版商
Springer Nature
发表日期
2017-06-17
DOI
10.1186/s12967-017-1239-z
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- EMT, CSCs, and drug resistance: the mechanistic link and clinical implications
- (2017) Tsukasa Shibue et al. Nature Reviews Clinical Oncology
- Tumour-infiltrating lymphocytes and the emerging role of immunotherapy in breast cancer
- (2017) Stephen J. Luen et al. PATHOLOGY
- An Acquired HER2 T798I Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant–Driven Breast Cancer
- (2017) Ariella B. Hanker et al. Cancer Discovery
- Identification of genetic determinants of breast cancer immune phenotypes by integrative genome-scale analysis
- (2017) Wouter Hendrickx et al. OncoImmunology
- Clinical Implications of ESR1 Mutations in Hormone Receptor-Positive Advanced Breast Cancer
- (2017) Tomas Reinert et al. Frontiers in Oncology
- Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide AE37 vaccine in breast cancer patients to prevent recurrence
- (2016) E. A. Mittendorf et al. ANNALS OF ONCOLOGY
- Targeting Cellular Signaling Pathways in Breast Cancer Stem Cells and its Implication for Cancer Treatment
- (2016) BRUNO RICARDO BARRETO PIRES et al. ANTICANCER RESEARCH
- Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00
- (2016) Giancarlo Pruneri et al. BREAST CANCER RESEARCH AND TREATMENT
- PlasmaESR1Mutations and the Treatment of Estrogen Receptor–Positive Advanced Breast Cancer
- (2016) Charlotte Fribbens et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study
- (2016) Rita Nanda et al. JOURNAL OF CLINICAL ONCOLOGY
- Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
- (2016) Arlene Chan et al. LANCET ONCOLOGY
- Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial
- (2016) Nadia Harbeck et al. LANCET ONCOLOGY
- Intrinsic HER2 V777L mutation mediates resistance to trastuzumab in a breast cancer patient
- (2016) Yosuke Hirotsu et al. MEDICAL ONCOLOGY
- HER2 expression identifies dynamic functional states within circulating breast cancer cells
- (2016) Nicole Vincent Jordan et al. NATURE
- Adaptive Randomization of Veliparib–Carboplatin Treatment in Breast Cancer
- (2016) Hope S. Rugo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
- (2016) Gabriel N. Hortobagyi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Palbociclib and Letrozole in Advanced Breast Cancer
- (2016) Richard S. Finn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immunothérapie et cancer du sein
- (2016) B. Verret et al. Oncologie
- Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer
- (2016) Sarat Chandarlapaty et al. JAMA Oncology
- Association of Stromal Tumor-Infiltrating Lymphocytes With Recurrence-Free Survival in the N9831 Adjuvant Trial in Patients With Early-Stage HER2-Positive Breast Cancer
- (2016) Edith A. Perez et al. JAMA Oncology
- Variation in the Incidence and Magnitude of Tumor-Infiltrating Lymphocytes in Breast Cancer Subtypes
- (2016) Sasha E. Stanton et al. JAMA Oncology
- Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials
- (2015) M. V. Dieci et al. ANNALS OF ONCOLOGY
- Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
- (2015) A. S. Coates et al. ANNALS OF ONCOLOGY
- Relevance of tumor-infiltrating lymphocytes in breast cancer
- (2015) Sathana Dushyanthen et al. BMC Medicine
- Upregulation of ER Signaling as an Adaptive Mechanism of Cell Survival in HER2-Positive Breast Tumors Treated with Anti-HER2 Therapy
- (2015) M. Giuliano et al. CLINICAL CANCER RESEARCH
- Sensitive Detection of Mono- and Polyclonal ESR1 Mutations in Primary Tumors, Metastatic Lesions, and Cell-Free DNA of Breast Cancer Patients
- (2015) P. Wang et al. CLINICAL CANCER RESEARCH
- Papillary and neuroendocrine breast lesions: the WHO stance
- (2015) Puay Hoon Tan et al. HISTOPATHOLOGY
- Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation–Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105
- (2015) Melinda L. Telli et al. JOURNAL OF CLINICAL ONCOLOGY
- Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2–Positive and Triple-Negative Primary Breast Cancers
- (2015) Carsten Denkert et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial
- (2015) Robert J. Motzer et al. JOURNAL OF CLINICAL ONCOLOGY
- Enhancing Endocrine Therapy for Hormone Receptor–Positive Advanced Breast Cancer: Cotargeting Signaling Pathways
- (2015) Stephen R. D. Johnston JNCI-Journal of the National Cancer Institute
- Anti-PD-L1 for metastatic triple-negative breast cancer
- (2015) Josefine Gibson LANCET ONCOLOGY
- The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
- (2015) Richard S Finn et al. LANCET ONCOLOGY
- Breast Tumor Heterogeneity: Source of Fitness, Hurdle for Therapy
- (2015) Shany Koren et al. MOLECULAR CELL
- Clinical relevance of host immunity in breast cancer: from TILs to the clinic
- (2015) Peter Savas et al. Nature Reviews Clinical Oncology
- Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer
- (2015) Nicholas C. Turner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer
- (2015) Gaia Schiavon et al. Science Translational Medicine
- Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype?
- (2015) Fanny Le Du et al. Oncotarget
- Enhancing Endocrine Therapy for Hormone Receptor–Positive Advanced Breast Cancer: Cotargeting Signaling Pathways
- (2015) Stephen R. D. Johnston JNCI-Journal of the National Cancer Institute
- Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab
- (2015) Roberto Salgado et al. JAMA Oncology
- Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial
- (2014) S. Loi et al. ANNALS OF ONCOLOGY
- Final report of the phase I/II clinical trial of the E75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in high-risk breast cancer patients
- (2014) E. A. Mittendorf et al. ANNALS OF ONCOLOGY
- The prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancer: a meta-analysis
- (2014) Ezzeldin M. Ibrahim et al. BREAST CANCER RESEARCH AND TREATMENT
- PD-1+ immune cell infiltration inversely correlates with survival of operable breast cancer patients
- (2014) Shenyou Sun et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Safely targeting cancer stem cells via selective catenin coactivator antagonism
- (2014) Heinz-Josef Lenz et al. CANCER SCIENCE
- Is the differentiation into molecular subtypes of breast cancer important for staging, local and systemic therapy, and follow up?
- (2014) Amir Sonnenblick et al. CANCER TREATMENT REVIEWS
- Emergence of Constitutively Active Estrogen Receptor- Mutations in Pretreated Advanced Estrogen Receptor-Positive Breast Cancer
- (2014) R. Jeselsohn et al. CLINICAL CANCER RESEARCH
- Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline
- (2014) Sharon H. Giordano et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Study of Iniparib Plus Gemcitabine and Carboplatin Versus Gemcitabine and Carboplatin in Patients With Metastatic Triple-Negative Breast Cancer
- (2014) Joyce O'Shaughnessy et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199
- (2014) Sylvia Adams et al. JOURNAL OF CLINICAL ONCOLOGY
- Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response
- (2014) Evandro de Azambuja et al. LANCET ONCOLOGY
- The Met receptor tyrosine kinase: A key player in oncogenesis and drug resistance
- (2014) Christiane R. Maroun et al. PHARMACOLOGY & THERAPEUTICS
- Hypoxia-inducible factors are required for chemotherapy resistance of breast cancer stem cells
- (2014) Debangshu Samanta et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis
- (2013) Denise A. Yardley et al. ADVANCES IN THERAPY
- Outcome in breast molecular subtypes according to nodal status and surgical procedures
- (2013) Chafika Mazouni et al. AMERICAN JOURNAL OF SURGERY
- Safety and Efficacy of Everolimus With Exemestane vs. Exemestane Alone in Elderly Patients With HER2-Negative, Hormone Receptor–Positive Breast Cancer in BOLERO-2
- (2013) Kathleen I. Pritchard et al. Clinical Breast Cancer
- Differential Response to Neoadjuvant Chemotherapy Among 7 Triple-Negative Breast Cancer Molecular Subtypes
- (2013) H. Masuda et al. CLINICAL CANCER RESEARCH
- Identification of Prognosis-Relevant Subgroups in Patients with Chemoresistant Triple-Negative Breast Cancer
- (2013) K.-D. Yu et al. CLINICAL CANCER RESEARCH
- The Continuum of Cancer Immunosurveillance: Prognostic, Predictive, and Mechanistic Signatures
- (2013) Jérôme Galon et al. IMMUNITY
- ESR1 ligand-binding domain mutations in hormone-resistant breast cancer
- (2013) Weiyi Toy et al. NATURE GENETICS
- Activating ESR1 mutations in hormone-resistant metastatic breast cancer
- (2013) Dan R Robinson et al. NATURE GENETICS
- Emerging targeted agents in metastatic breast cancer
- (2013) Dimitrios Zardavas et al. Nature Reviews Clinical Oncology
- Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974
- (2013) J. Liu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Tumor-infiltrating lymphocytes, breast cancer subtypes and therapeutic efficacy
- (2013) Sherene Loi OncoImmunology
- Potential of Selective Estrogen Receptor Modulators as Treatments and Preventives of Breast Cancer
- (2012) Jing Peng et al. Anti-Cancer Agents in Medicinal Chemistry
- The evolving concept of cancer and metastasis stem cells
- (2012) Irène Baccelli et al. JOURNAL OF CELL BIOLOGY
- TBCRC 001: Randomized Phase II Study of Cetuximab in Combination With Carboplatin in Stage IV Triple-Negative Breast Cancer
- (2012) Lisa A. Carey et al. JOURNAL OF CLINICAL ONCOLOGY
- Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study
- (2012) Jean-Yves Pierga et al. LANCET ONCOLOGY
- Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
- (2012) Sunil Verma et al. NEW ENGLAND JOURNAL OF MEDICINE
- Activating HER2 Mutations in HER2 Gene Amplification Negative Breast Cancer
- (2012) Ron Bose et al. Cancer Discovery
- Androgen receptor expression in primary breast cancer and its predictive and prognostic value in patients treated with neoadjuvant chemotherapy
- (2011) Sibylle Loibl et al. BREAST CANCER RESEARCH AND TREATMENT
- Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)
- (2011) Laura J. Esserman et al. BREAST CANCER RESEARCH AND TREATMENT
- Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
- (2011) Brian D. Lehmann et al. JOURNAL OF CLINICAL INVESTIGATION
- Prospective Study Evaluating the Impact of Tissue Confirmation of Metastatic Disease in Patients With Breast Cancer
- (2011) Eitan Amir et al. JOURNAL OF CLINICAL ONCOLOGY
- PI3K Pathway Mutations and PTEN Levels in Primary and Metastatic Breast Cancer
- (2011) A. M. Gonzalez-Angulo et al. MOLECULAR CANCER THERAPEUTICS
- Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
- (2011) José Baselga et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tremelimumab in Combination with Exemestane in Patients with Advanced Breast Cancer and Treatment-Associated Modulation of Inducible Costimulator Expression on Patient T Cells
- (2010) R. H. Vonderheide et al. CLINICAL CANCER RESEARCH
- Classical Cyclophosphamide, Methotrexate, and Fluorouracil Chemotherapy Is More Effective in Triple-Negative, Node-Negative Breast Cancer: Results From Two Randomized Trials of Adjuvant Chemoendocrine Therapy for Node-Negative Breast Cancer
- (2010) Marco Colleoni et al. JOURNAL OF CLINICAL ONCOLOGY
- Associations of Breast Cancer Risk Factors With Tumor Subtypes: A Pooled Analysis From the Breast Cancer Association Consortium Studies
- (2010) Xiaohong R. Yang et al. JNCI-Journal of the National Cancer Institute
- Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
- (2010) Andrew Tutt et al. LANCET
- Minireview: Basal-Like Breast Cancer: From Molecular Profiles to Targeted Therapies
- (2010) Daniel J. Toft et al. MOLECULAR ENDOCRINOLOGY
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer
- (2009) Carsten Denkert et al. JOURNAL OF CLINICAL ONCOLOGY
- Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution
- (2009) Sohrab P. Shah et al. NATURE
- Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features
- (2009) C. J. Creighton et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses
- (2008) David Cameron et al. BREAST CANCER RESEARCH AND TREATMENT
- Is There a Role for Circulating Tumor Cells in the Management of Breast Cancer?
- (2008) D. F. Hayes et al. CLINICAL CANCER RESEARCH
- Genetic Changes of Wnt Pathway Genes Are Common Events in Metaplastic Carcinomas of the Breast
- (2008) M. J. Hayes et al. CLINICAL CANCER RESEARCH
- Targeted therapeutics for cancer treatment: major progress towards personalised molecular medicine
- (2008) Paul Workman et al. CURRENT OPINION IN PHARMACOLOGY
- Breast Cancer Subtype Approximated by Estrogen Receptor, Progesterone Receptor, and HER-2 Is Associated With Local and Distant Recurrence After Breast-Conserving Therapy
- (2008) Paul L. Nguyen et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic Significance of Nottingham Histologic Grade in Invasive Breast Carcinoma
- (2008) Emad A. Rakha et al. JOURNAL OF CLINICAL ONCOLOGY
- Intrinsic Resistance of Tumorigenic Breast Cancer Cells to Chemotherapy
- (2008) X. Li et al. JNCI-Journal of the National Cancer Institute
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now